Literature DB >> 2612052

Immune status and response to immunization with polysaccharide vaccines of a healthy, congenitally asplenic woman.

P J McElroy1, F I Henderson, D L Brown.   

Abstract

We describe the immune status of a congenitally asplenic, otherwise healthy and anatomically normal 30-year-old woman. As in surgically asplenic subjects, she had Howell-Jolly bodies in a blood smear, increased B lymphocyte and decreased T helper and suppressor lymphocyte percentages, and a slightly lower than average T helper/suppressor ratio. Because of the increased risk of infection with capsulate bacteria in asplenic patients, the subject was immunized with Pneumovax and meningococcal vaccine and her serum antibody responses were investigated. She was found to have subnormal IgG antibody titres which did not increase on immunization, although the subclass distribution of anti-pneumococcal antibody was normal with IgG2 predominating. IgM antibody titres were higher than in a pool of normal adult human sera, while IgA levels increased substantially as in normal subjects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2612052      PMCID: PMC1534820     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Cardiac clinics. CXLVIII. Congenital cardiac disease and asplenia; report of seven cases.

Authors:  W S LYONS; D G HANLON; H F HELMHOLZ; J W DUSHANE; J E EDWARDS
Journal:  Proc Staff Meet Mayo Clin       Date:  1957-05-29

2.  Congenital absence of the spleen in an adult; report of a case associated with recurrent Waterhouse-Friderichsen syndrome.

Authors:  R M MYERSON; W A KOELLE
Journal:  N Engl J Med       Date:  1956-06-14       Impact factor: 91.245

3.  Isolated congenital asplenia: an occult case of overwhelming sepsis.

Authors:  R Honigman; P Lanzkowsky
Journal:  Am J Dis Child       Date:  1979-05

4.  Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization.

Authors:  R H Stevens; A Saxon
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

5.  Peripheral blood leucocyte subpopulations in patients splenectomized for trauma.

Authors:  A Ferrante; P A Drew; G K Kiroff; H Zola
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

6.  Comparison of ELISA and RIA for measurement of pneumococcal antibodies before and after vaccination with 14-valent pneumococcal capsular polysaccharide vaccine.

Authors:  M Koskela; M Leinonen
Journal:  J Clin Pathol       Date:  1981-01       Impact factor: 3.411

7.  Studies on immunological paralysis. VI. Thymic-independence of tolerance and immunity to type 3 pneumococcal polysaccharide.

Authors:  J G Howard; G H Christie; B M Courtenay; E Leuchars; A J Davies
Journal:  Cell Immunol       Date:  1971-12       Impact factor: 4.868

8.  Sepsis and congenital asplenia.

Authors:  J D Waldman; A Rosenthal; A L Smith; S Shurin; A S Nadas
Journal:  J Pediatr       Date:  1977-04       Impact factor: 4.406

9.  Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.

Authors:  M S Simberkoff; A P Cross; M Al-Ibrahim; A L Baltch; P J Geiseler; J Nadler; A S Richmond; R P Smith; G Schiffman; D S Shepard
Journal:  N Engl J Med       Date:  1986-11-20       Impact factor: 91.245

10.  Familial asplenia, other malformations, and sudden death.

Authors:  A L Katcher
Journal:  Pediatrics       Date:  1980-03       Impact factor: 7.124

View more
  3 in total

1.  Complications of asplenia and hyposplenism--persistent uncertainties.

Authors:  B Styrt
Journal:  West J Med       Date:  1992-10

2.  The spleen? Who needs it anyway?

Authors:  M Hazlewood; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

3.  Northern region asplenia register--analysis of first two years.

Authors:  G P Spickett; J Bullimore; J Wallis; S Smith; P Saunders
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.